Logo image of ALSEN.PA

SENSORION SA (ALSEN.PA) Stock Fundamental Analysis

EPA:ALSEN - Euronext Paris - Matif - FR0012596468 - Common Stock - Currency: EUR

0.327  0 (-0.91%)

Fundamental Rating

3

ALSEN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 67 industry peers in the Biotechnology industry. The financial health of ALSEN is average, but there are quite some concerns on its profitability. ALSEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALSEN has reported negative net income.
ALSEN had a negative operating cash flow in the past year.
ALSEN had negative earnings in each of the past 5 years.
In the past 5 years ALSEN always reported negative operating cash flow.
ALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

ALSEN has a Return On Assets (-29.09%) which is in line with its industry peers.
ALSEN has a Return On Equity (-36.00%) which is in line with its industry peers.
Industry RankSector Rank
ROA -29.09%
ROE -36%
ROIC N/A
ROA(3y)-45.38%
ROA(5y)-34.99%
ROE(3y)-69.45%
ROE(5y)-51.62%
ROIC(3y)N/A
ROIC(5y)N/A
ALSEN.PA Yearly ROA, ROE, ROICALSEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALSEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALSEN.PA Yearly Profit, Operating, Gross MarginsALSEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

ALSEN has more shares outstanding than it did 1 year ago.
ALSEN has more shares outstanding than it did 5 years ago.
ALSEN has a better debt/assets ratio than last year.
ALSEN.PA Yearly Shares OutstandingALSEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALSEN.PA Yearly Total Debt VS Total AssetsALSEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 2.39 indicates that ALSEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
ALSEN has a Altman-Z score of 2.39. This is in the better half of the industry: ALSEN outperforms 68.66% of its industry peers.
ALSEN has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ALSEN has a better Debt to Equity ratio (0.01) than 79.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.39
ROIC/WACCN/A
WACCN/A
ALSEN.PA Yearly LT Debt VS Equity VS FCFALSEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 6.28 indicates that ALSEN has no problem at all paying its short term obligations.
ALSEN has a Current ratio of 6.28. This is amongst the best in the industry. ALSEN outperforms 80.60% of its industry peers.
ALSEN has a Quick Ratio of 6.28. This indicates that ALSEN is financially healthy and has no problem in meeting its short term obligations.
ALSEN has a better Quick ratio (6.28) than 83.58% of its industry peers.
Industry RankSector Rank
Current Ratio 6.28
Quick Ratio 6.28
ALSEN.PA Yearly Current Assets VS Current LiabilitesALSEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

ALSEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.21%, which is quite impressive.
EPS 1Y (TTM)55.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 41.98% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALSEN will show a very strong growth in Revenue. The Revenue will grow by 66.34% on average per year.
EPS Next Y11.11%
EPS Next 2Y18.64%
EPS Next 3Y14.47%
EPS Next 5Y41.98%
Revenue Next Year95.58%
Revenue Next 2Y47.68%
Revenue Next 3Y15.46%
Revenue Next 5Y66.34%

3.3 Evolution

ALSEN.PA Yearly Revenue VS EstimatesALSEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ALSEN.PA Yearly EPS VS EstimatesALSEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALSEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALSEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSEN.PA Price Earnings VS Forward Price EarningsALSEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSEN.PA Per share dataALSEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as ALSEN's earnings are expected to grow with 14.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.64%
EPS Next 3Y14.47%

More info and screens

0

5. Dividend

5.1 Amount

ALSEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSORION SA

EPA:ALSEN (7/18/2025, 7:00:00 PM)

0.327

0 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-14 2025-03-14/amc
Earnings (Next)09-16 2025-09-16
Inst Owners53.64%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap98.32M
Analysts86.67
Price Target1.91 (484.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.46%
PT rev (3m)-29.69%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)128.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.09%
ROE -36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.38%
ROA(5y)-34.99%
ROE(3y)-69.45%
ROE(5y)-51.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.28
Quick Ratio 6.28
Altman-Z 2.39
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)191.05%
Cap/Depr(5y)144.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.9%
EPS Next Y11.11%
EPS Next 2Y18.64%
EPS Next 3Y14.47%
EPS Next 5Y41.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year95.58%
Revenue Next 2Y47.68%
Revenue Next 3Y15.46%
Revenue Next 5Y66.34%
EBIT growth 1Y-27.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.76%
EBIT Next 3Y13.96%
EBIT Next 5Y38.57%
FCF growth 1Y-0.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.23%
OCF growth 3YN/A
OCF growth 5YN/A